PME - Pro Medicus Limited (ASX) - Share Price and News

Pro Medicus Limited
AU ˙ ASX ˙ AU000000PME8
$298.23 ↑1.88 (0.63%)
2025-09-05
SHARE PRICE
Overview
Pro Medicus Limited is an Australian-based company specializing in radiology information systems (RIS), picture archiving and communication systems (PACS), and other advanced medical imaging software. Founded in 1983, the company has evolved to become a prominent provider in the healthcare sector, notably in medical imaging and diagnostics technologies. Pro Medicus leverages its Visage 7 platform to deliver high-performance, scalable imaging solutions that support server-side processing and streamline diagnostic workflows across various medical settings. This technology has facilitated substantial advancements in reading efficiency and diagnostic accuracy in the health sector. The company has successfully expanded its footprint by securing multiple high-value contracts with leading hospital networks in North America, Europe, and Australia, enhancing its market presence and reinforcing its expertise in healthcare imaging solutions.
AI+ Ask Fintel’s AI assistant about Pro Medicus Limited.
Thinking about good questions…
Basic Stats

The share price of Pro Medicus Limited as of 5 September 2025 is $298.23 / share. This is a decrease of -0.19% from the prior week. The market cap (or net worth) of Pro Medicus Limited as of 5 September 2025 is $31,153.97 MM.

The Factor Analysis chart (below right) shows a view of Pro Medicus Limited from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.

For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.

Market Cap 31,153.97 MM
EV 31,046.49 MM
Shares Out. 104.46 MM
Earnings Date
EPS (TTM) 1.10
Dividend Yield 0.20 %
Ex-Dividend Date 2025-09-03
Borrow Rate 0.92
Short Shares Avail. 0.00 MM
Short Interest 1.88 MM
Short Float 3.54 %
Days to Cover 9.19 days
Risk Free Rate 4.17 %
Price Change (1 yr)
Volatility (1 yr) 0.37
Beta 1.69
Sharpe Ratio (1 yr)
Sortino Ratio (1 yr)
PE Ratio 270.39
Price/Book 121.24
Price/TBV 131.90
Book/Market 0.01
EBIT/EV 0.01
EBIT(3yr avg)/EV 0.00
ROA 0.45
ROE 0.61
ROIC 0.44
CROIC 0.18
OCROIC 0.43
Implied Volatility
Put/Call OI Ratio
Growth 90.90 /100
Profitability 96.72 /100
Quality Score 92.79 /100
Value Score 35.47 /100
Momentum Score 51.82 /100
Stability (Low Vol) Score 59.43 /100
Analyst Sentiment 30.60 /100
Fund Sentiment 42.46 /100
Insider Sentiment
Officer Sentiment
Dividend Score 27.21 /100
QVM Score 56.28 /100
Piotroski F-SCORE 7.00 /9
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target

The average one-year price target for Pro Medicus Limited is $324.19. The forecasts range from a low of $222.20 to a high of $367.50. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.

Update Frequency: Monthly

Record Date Projection Date High Low Median Average
2025-09-02 2026-09-02 367.50 222.20 328.03 324.19
Stock Upgrades/Downgrades

This card shows analyst upgrades/downgrades for Pro Medicus Limited. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.

The standard analyst ratings are generally as follows:
  • Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
  • Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
  • Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.

When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.

The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.

Date Analyst Prior Latest
Recommendation
Action
2023-03-23 BELL POTTER SECURITIES Sell Hold Upgrade
2023-02-21 BELL POTTER SECURITIES Hold Sell Downgrade
2023-02-16 MOELIS AUSTRALIA SECURITIES Hold Hold Maintains
2023-02-15 WILSONS Overweight Overweight Maintains
2022-09-01 BELL POTTER SECURITIES Buy Hold Downgrade
2022-06-03 BELL POTTER SECURITIES Hold Buy Upgrade
2021-09-30 BELL POTTER SECURITIES Hold Hold Maintains
2021-02-18 MOELIS AUSTRALIA SECURITIES Hold Hold Maintains
2023-05-15 MOELIS AUSTRALIA SECURITIES Hold Hold Maintains
2023-03-22 BELL POTTER SECURITIES Sell Hold Upgrade
2023-02-20 BELL POTTER SECURITIES Hold Sell Downgrade
2023-02-14 WILSONS Overweight Overweight Maintains
2022-08-31 BELL POTTER SECURITIES Buy Hold Downgrade
2022-06-02 BELL POTTER SECURITIES Hold Buy Upgrade
2021-09-29 BELL POTTER SECURITIES Hold Hold Maintains
2021-02-17 MOELIS AUSTRALIA SECURITIES Hold Hold Maintains
2023-12-19 BELL POTTER SECURITIES Hold Hold Maintains
2023-10-25 MOELIS AUSTRALIA SECURITIES Hold Hold Maintains
2023-09-26 WILSONS Overweight Overweight Maintains
2023-08-31 BELL POTTER SECURITIES Hold Hold Maintains
2023-08-30 WILSONS Overweight Overweight Maintains
2023-08-16 MOELIS AUSTRALIA SECURITIES Hold Hold Maintains
2023-05-16 MOELIS AUSTRALIA SECURITIES Hold Hold Maintains
2023-08-30 BELL POTTER SECURITIES Hold Hold Maintains
2023-08-29 WILSONS Overweight Overweight Maintains
2023-08-15 MOELIS AUSTRALIA SECURITIES Hold Hold Maintains
2024-07-03 BELL POTTER SECURITIES Hold Hold Maintains
2024-07-01 MACQUARIE RESEARCH Outperform Outperform Maintains
2024-02-15 MOELIS AUSTRALIA SECURITIES Hold Hold Maintains
2024-01-29 BELL POTTER SECURITIES Hold Hold Maintains
2023-12-18 BELL POTTER SECURITIES Hold Hold Maintains
2023-10-24 MOELIS AUSTRALIA SECURITIES Hold Hold Maintains
2023-09-25 WILSONS Overweight Overweight Maintains
2025-03-30 MACQUARIE RESEARCH Neutral Neutral Maintains
2025-03-26 BELL POTTER SECURITIES Hold Buy Upgrade
2025-03-25 JEFFERIES Hold Hold Maintains
2025-03-22 E&P Neutral Neutral Maintains
2025-02-13 MOELIS AUSTRALIA SECURITIES Hold Hold Maintains
2025-02-12 WILSONS Overweight Overweight Maintains
2024-12-04 BELL POTTER SECURITIES Hold Hold Maintains
2024-11-28 E&P Neutral Neutral Maintains
2024-11-18 MACQUARIE RESEARCH Outperform Neutral Downgrade
2024-10-28 MACQUARIE RESEARCH Outperform Outperform Maintains
2024-08-14 MOELIS AUSTRALIA SECURITIES Hold Hold Maintains
2025-01-06 WILSONS Overweight Overweight Maintains
2025-04-07 BELL POTTER SECURITIES Buy Hold Downgrade
2025-07-16 MACQUARIE RESEARCH Neutral Neutral Maintains
2025-07-14 BELL POTTER SECURITIES Buy Buy Maintains
2025-07-03 MOELIS AUSTRALIA SECURITIES Hold Hold Maintains
2025-07-02 JEFFERIES Hold Hold Maintains
2025-07-02 E&P Neutral Neutral Maintains
2025-07-02 BELL POTTER SECURITIES Hold Buy Upgrade
Other Listings
DE:PMC
US:PMCUF
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista